WUXI BIOLOGICS- WILL PROVIDE AN EXCLUSIVE LICENSE TO GSK FOR ONE PRECLINICAL BI-SPECIFIC ANTIBODY AND OPTION OF 3 ADDITIONAL BI-/MULTI-SPECIFIC TCE ANTIBODIES